ImmunityBio's ANKTIVA Plus BCG Shows 71% Complete Response Rate in Bladder Cancer Study

ImmunityBio announced published Phase 2/3 results in the Journal of Urology showing durable responses with ANKTIVA combined with BCG in bladder cancer. The study involved patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Long-term findings showed sustained disease control, supporting the potential to avoid or delay bladder removal surgery. Most treatment-related adverse events were mild or moderate, with no life-threatening or fatal treatment-related events reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via (Ref. ID: 20261016061704) on October 16, 2026, and is solely responsible for the information contained therein. (C)